



AKZO NOBEL

Rob Frohn, CFO

Q3 2007 Results

“Year of Transformation”

October 23, 2007



Q3 2007 highlights – strong performance in transformational year

- Good 5% autonomous growth
- Net income before incidentals increased 16%
- Recommended cash offer for ICI
- Akzo Nobel tops DJSI sustainability ranking
- Interim dividend increased to EUR 0.40 per share



Q3 OPERATIONAL PERFORMANCE



EUR mln	Q3 2007	Δ%
Revenues	2,600	2
EBITDA*	333	7
EBIT*	244	11
Net income*	156	16
EPS, in EUR	0.58	23
Q3, %	2007	2006
EBITDA margin*	12.8	12.2
EBIT margin*	9.4	8.6
Moving average ROI	15.6	13.5

* Before incidentals



Car Refinishes – Sikkens® Autoclear® UV





<i>EUR mln</i>	Q3 2007	Δ%
Revenues	1,686	3
EBITDA*	209	7
EBIT*	174	8

Q3, %	2007	2006
EBITDA margin*	12.4	12.0
EBIT margin*	10.3	9.8
Moving average ROI	20.3	20.5

* *Before incidentals.*



Coatings – solid performance, EBITDA up



- Decorative Coatings
 - bottom line performance significantly improved
 - ongoing restructuring programs paying off
- Industrial activities
 - sustained performance, despite North America weakness
 - acquisition Chemcraft completed
- Marine & Protective Coatings – continued excellent performance
- Car Refinishes – on track



Surfactants – the road to China





Chemicals – strong performance; record ROI



EUR mln	Q3 2007	Δ%
Revenues	911	5
EBITDA*	152	13
EBIT*	102	26

Q3, %	2007	2006
EBITDA margin*, in %	16.7	15.6
EBIT margin*, %	11.2	9.3
Moving average ROI	21.1	18.5

*Before incidentals.



Chemicals – strong performance; record ROI



- Pulp & Paper Chemicals – improved pricing drives autonomous growth
- Base Chemicals – robust performance due to higher demand and prices
- Functional Chemicals – good performance
- Surfactants – making progress on roadmap
- Polymer Chemicals – in line with strong 2006



ORGANON BIOSCIENCES



<i>EUR mln</i>	Q3 2007	Δ%
Revenues	918	2
EBIT*	205	39

Q3, %	2007	2006
EBIT margin*, in %	22.3	16.4
S&D in % revenues	27.3	29.3
R&D in % revenues	15.7	15.5

* *Before incidentals.*



Organon BioSciences – good quarter



- Organon strong performance of key products
- Organon operating income before incidentals EUR 117 mln
- Record quarter for Intervet – EBIT margin of 26.1%
- Profitable new product introductions increased Intervet's margins

- Sales agreement signed with Schering-Plough
- Schering-Plough received EU clearance
- Closing expected before end of 2007



Q3 FINANCIAL PERFORMANCE



Robust financial position



- Strong balance sheet
- EUR 1.6 billion share buyback completed
- Working capital up – growth and one-off items
- Capex EUR 240 mln (2006: EUR 235 mln); 97% of depreciation



AGENDA 2007

- Transfer of Organon BioSciences before year-end
- Prepare integration of ICI
- Calendar:
 - November 5, 2007 – EGM
 - March 6, 2008 – Annual Results 2007
- Deliver on 2007 growth and profit improvement objectives

Creating one of the world's leading industrial companies



“Year of Transformation”

Q&A



Safe Harbor Statement*



This presentation contains statements which address such key issues as Akzo Nobel's growth strategy, future financial results, market positions, product development, pharmaceutical products in the pipeline, and product approvals. Such statements should be carefully considered, and it should be understood that many factors could cause forecasted and actual results to differ from these statements. These factors include, but are not limited to, price fluctuations, currency fluctuations, progress of drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, pensions, physical and environmental risks, legal issues, and legislative, fiscal, and other regulatory measures. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies. For a more comprehensive discussion of the risk factors affecting our business please see our Annual Report on Form 20-F filed with the United States Securities and Exchange Commission, a copy of which can be found on the company's corporate website www.akzonobel.com.

**Pursuant to the U.S. Private Securities Litigation Reform Act 1995.*